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Abstract
Cervical spondylotic myelopathy (CSM) is the most common spinal cord disorder and a major cause of disability in
adults. Improvements following surgical decompression are limited and patients often remain severely disabled.
Post mortem studies indicate that CSM is associated with profound axonal loss. However, our understanding of the
pathophysiology of CSM remains limited.
To investigate the hypothesis that axonal plasticity plays a role in the recovery following surgical decompression,
we adopted a novel preclinical model of mild to moderate CSM. Spinal cord compression resulted in significant
locomotor deterioration, increased expression of the axonal injury marker APP, and loss of serotonergic fibres.
Surgical decompression partially reversed the deficits and attenuated APP expression. Decompression was also
associated with axonal sprouting, reflected in the restoration of serotonergic fibres and an increase of GAP43
expression. The re-expression of synaptophysin indicated the restoration of functional synapses following
decompression. Promoting axonal plasticity may therefore be a therapeutic strategy for promoting neurological
recovery in CSM.
Introduction
Cervical Spondylotic Myelopathy (CSM) is the most com-
mon spinal cord disorder and one of the major causes of
disability in adulthood [35]. It is induced by degenerative
changes occurring in the intervertebral discs triggering
bony and ligamentous hypertrophy, which result in nar-
rowing of the cervical canal. Ultimately, tethering and
compression cause injury of the spinal cord and increasing
neurological deficits [2, 3]. The cellular events leading
from compression to myelopathic changes are less clear.
Current evidence suggests that mechanical compromise
results in ischemia and triggers axonal injury, inflamma-
tion, and apoptosis [2, 26, 42].
Although not without controversy [38], the accepted
mainstay of treatment, especially for more severe cases
of CSM, is surgical decompression [8]. A recent North
American study of CSM confirmed that surgery can lead
to significant improvements in CSM [16, 17]. Partial re-
versal of symptoms occurs after surgery over 3–12
months. This time frame implicates inherent regenera-
tive or plastic changes within the spinal cord. Neverthe-
less, many patients remain disabled [29], and there are
nonsurgical treatments available for improving outcome
for CSM.
Human post mortem studies suggest that the early
phase of CSM affects the lateral funiculi that contain the
lateral corticospinal tracts, resulting in axonal loss [9,
25, 40]. This corresponds well with the observation that
spastic gait, an upper motor neuron sign, is one of the
earliest signs of CSM. Later stages affect the posterior
columns and the central grey matter [25]. Furthermore,
degeneration of anterior horn motor neurons at the level
* Correspondence: mrk25@cam.ac.uk
1Department of Clinical Neurosciences, Anne McLaren Laboratory, Wellcome
Trust-MRC Cambridge Stem Cell Institute, John van Geest Centre for Brain
Repair, Academic Neurosurgery Unit, University of Cambridge, Cambridge
Biomedical Campus, West Forvie Building, Forvie Site, Robinson Way,
Cambridge CB2 0SZ, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dhillon et al. Acta Neuropathologica Communications  (2016) 4:89 
DOI 10.1186/s40478-016-0359-7
of spinal cord compression can result in a corresponding
lower motor neuron deficiency. Morphologically these
changes manifest themselves as degeneration of sensory
axons and necrosis and cavitation of the central grey
matter. As a result, loss of sensation, proprioception and
sphincter control occurs. Another feature of CSM is
myelin loss [25, 39, 51]. However, the extent to which
there is primary demyelination as a result of oligo-
dendrocyte pathology or myelin loss secondary to axonal
degeneration remains unclear.
Existing models mimicking chronic cord compression
in rats include insertion of expandable polymers [50],
adjustable screws [33], and calcification-inducing poly-
mers [28]. These result in loss of neurons, predomin-
antly in the grey matter of the ventral horns at the
lesion epicentre. Preferential neuronal loss has also been
demonstrated in canine screw compression models
[21] and twy-twy mouse models [1]. In addition, de-
myelination has been observed in some CSM models
[28, 51], although myelin pallor or frank myelin loss
is not generally present in expandable polymer animal
models [30, 50].
Only two studies in the literature reported on the
consequences of surgical decompression in animal
models of CSM. The first study involved a canine
model, in which cord compression was achieved by
insertion of a posterior sublaminar Teflon washer and
an anterior vertebral screw. Surgical decompression
after 37–50 weeks resulted in neurological improve-
ment [21]. However, the authors noted that basic
histological findings showed little correlation with
functional recovery; a cellular analysis was not con-
ducted. More recently, Karadimas et al. demonstrated
that surgical decompression leads to improved blood
flow and can cause ischemia-reperfusion injury in a
rat model. This elegant study provided evidence of
oxidative damage in neurons at the previously com-
pressed level, and that the damage can be attenuated
by the sodium channel blocker riluzole [27].
On the basis of the extensive axonal degeneration
seen in post mortem studies of CSM patients and in
preclinical models, we theorised that axonal plasticity
plays a role in the recovery following surgical decom-
pression. To investigate this hypothesis, we developed
a novel rat model of mild to moderate CSM in which
transient cervical spinal cord compression is induced
by sublaminar insertion of a water-absorbing polyur-
ethane elastomer. Behavioral tests were conducted at
weekly intervals for 10 weeks. The spinal cords were
then surgically decompressed and the animals
observed for further five weeks. At the end of the ex-
periment, animals were sacrificed to study the cellular
events that occur as a consequence of chronic cord
compression and surgical decompression.
Materials and methods
Animal experiments
The present series of experiments involved a total of fif-
teen purpose-bred adult male Sprague-Dawley rats weigh-
ing 300–400 g (mean 342 g, Harlan Laboratories, Bicester,
UK) that were randomly assigned to three experimental
groups (n = 5 per group). 1) Control group receiving two
sets of sham surgery without implantation of a polymer.
2) Compression group, in which a polymer was implanted
and sham surgery was conducted at the time point of de-
compression. 3) Decompression group, in which a poly-
mer was implanted and subsequently removed.
All experimental protocols were approved by the Home
Office UK under the Animals Scientific Procedures Act
1986 incorporating Amendment Regulations SI 2012/
3039. Animals were housed in environmentally enriched
cages in groups of four, with 12 hour light cycles at room
temperature of 22 degrees Celsius and fed ad libitum on
Rat Diet 512 pellets (LabDiet, St Louis, USA).
Surgical implantation of expandable polymers
Anaesthesia was induced using inhaled isofluorane gas
(Sigma-Aldrich, Gillingham, UK) tritrated to 2.5 % and
maintained at 2 %. A 3.5 cm midline skin incision was
made from the inion to the vertebra prominens. Midline
sharp dissection was performed to expose the deep para-
spinal extensor musculature. This deep layer was pre-
served with subperiosteal dissection of the muscle
attachments to the dorsal laminar surface. The cervical
laminae were identified by counting from C1. The liga-
mentum flavum at C4/5 and C2/3 was excised to expose
the underlying thecal sac. The implant was passed crani-
ally from the C4/5 epidural space to the C2/3 laminar
interspace, whilst minimizing dorsoventral displacement
of the thecal sac and secured on the dorsal aspect of the
laminae at C3 and C4. Layered closure was performed
and sutures removed on day 7 post operatively.
Compression material
A water-absorbing polyurethane elastomer (Aquaprene
G, Sanyo Chemical Industries, Kyoto, Japan) was used.
This was based on the polymer of an established pre-
clinical model which reached a volume of 230 % over
24 h and remained stable for 16 days thereafter [30].
Sections measuring 0.70 mm (ventrodorsal) × 3 mm
(mediolateral) × 5 mm (rostrocaudal) were cut and steri-
lised using ethylene oxide to prevent expansion from
steam sterilisation.
Optimisation of the compression model
In preliminary experiments, implants of varying size and
cervical level were trialed. Implants measuring 0.60 mm
were found to produce minimal or no deficits and im-
plants measuring up to 0.85 mm were found to induce
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severe neurological deficits. Implants of size 0.7 mm
produced a moderate neurological deficit whose cadence
most closely resembled the human condition. Cervical
levels C5-7 were also trialed however these resulted in
severe deficits, which prevented longer term investiga-
tion of the animals.
Sham surgery
Animals assigned to the sham surgery group underwent
the same preparation, exposure and closure as the com-
pression group. The implant was passed into the dorsal
epidural space and then removed.
Surgical decompression
Animals assigned to the decompression group under-
went the same preparation, exposure and closure as the
compression group. The implant was removed through
the caudal laminar interspace avoiding sudden ventro-
dorsal angulation. A single level bilateral laminectomy of
the inferior level, namely C4, was performed.
Neurobehavioural assessments
Animals were subjected to the following neurobeha-
vioural tests.
The Basso, Beattie, and Bresnahan (BBB) score assessed
joint movement, weight bearing, paw placement, stepping,
forelimb-hindlimb co-ordination, paw rotation at contact
and lift off phases of gait, toe clearance, tail elevation, and
trunk stability [4] in an open field measuring 95 × 45 cm.
Four minute videos were recorded of each animal at each
time-point and scored in random order to blind the asses-
sor to time-points.
Forepaw and hindpaw slips were assessed using a
100 × 10 cm walkway with a wire floor consisting of
1.5 × 1.5 cm squares of wire thickness 1.6 mm, adapted
from Bradbury and colleagues [7]. Videos were recorded
of each animal at each time-point completing the walk 3
times and scored in random order. A slip was re-
corded if the paw fell below the plane of the grid,
and the average number of slips after three walks cal-
culated to give a score.
Stride length and width were assessed by inking the
forepaws and allowing the rat to ambulate 3 times along
a 1 m × 10 cm wooden walkway, adapted from Kunkel-
Bagden et al. [31]. Stride width was taken as the distance
between the central pads of the forepaws measured over
3 steps and averaged. Stride length was measured as the
distance between two consecutive steps, measured over
3 steps and then averaged.
Electrophysiology
Sensory evoked potentials were performed as terminal
procedures on 2 rats that were randomly selected from
each group. Anaesthesia was induced using 5 mg/kg of
xylazine hydrochloride (Bayer, Cambridge, UK) and
100 mg/kg of ketamine hydrochloride (Pfizer, Kent, UK)
injected intra-peritoneally. Three contact sites were ex-
posed; the tibial nerve in the left posterior thigh, the gra-
cile nucleus in the brainstem at the level of the obex,
accessed through a posterior suboccipital approach, and
the primary sensory cortex through a burrhole 1.5 mm
anterolateral to bregma.
Stimuli were delivered to the tibial nerve via a cuff
electrode with the nerve in contact with 2 silver wires
5 mm apart. Square wave pulses of 0.2 ms duration (best
for stimulating smaller fibres), at 2 Hz, were delivered
using an A-M Systems Isolated Pulse Stimulator Model
2100 (A-M Systems, Se-quim, USA). Signals were sam-
pled simultaneously from the ipsilateral gracile nucleus
and from the contralateral sensorimotor cortex via insu-
lated silver wire electrodes. Nerve action potentials were
amplified 2000 times (Neurolog NL824) filtered (5Hz to
5 kHz) and any mains contamnination removed using a
Humbug device (Digitimer UK). Data were sampled at
25 kHz using via a Power 1401 acquisition system and
Spike 2 data analysis software (Cambridge Electronic
Design, Cambridge, UK).
Stimulus intensity was determined relative to the
threshold of the fastest conducting fibres in the tibial
nerve. This was the lowest current required to activate a
compound action potential larger than the background
noise and was typically 20–40 microamps. To assess re-
sponses in the gracile and sensorimotor cortex the nerve
was then activated at four times that threshold current
(T). For each measure an average of 100 SEP responses
was taken, responses evoked from the tibial nerve and
recorded at the gracile nucleus were recorded as spinal
latencies, the fastest of which would be direct (no synap-
tic relays). Responses recorded at the sensory cortex
were cortical latencies, comprising spinal latencies, plus
synaptic delays at the gracile nucleus and sensory thal-
amus. Latencies were converted to velocities. Ampli-
tudes of the spinal and cortical potentials were also
recorded.
Tissue processing
All histology was performed at the end of the experi-
ment, after 10 weeks of compression and 5 weeks after
decompression. Animals were administered 50 mg/kg of
sodium pentobarbital intra-peritoneally (Sigma-Aldrich,
Gillingham, UK). The left ventricle was catheterised via
a midline sternotomy. Heparinised saline 10,000U/
1000 ml (Sigma-Aldrich, Gillingham, UK) was perfused
at 140 mmHg for 3 min followed by 4 % paraformalde-
hyde (Sigma-Aldrich, Gillingham, UK) at 140 mmHg for
7 min. The neural axis was removed en bloc and post-
fixed in 4 % PFA overnight. Tissues were left in 30 % su-
crose overnight for cryoprotection then frozen in Tissue-
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Tek® OCT matrix (TissueTek, Sakura Finetek, Thatcham,
UK) at −70 °C. Longitudinal sections of cervical cord of
12 μm thickness spanning 5 mm above and below the le-
sion were made on a cryostat (OTF 5030, Bright
Instruments, Huntingdon, UK), mounted onto polylysine
coated slides (Menzel-Glaser, Thermo Fisher Scientific,
Waltham, USA) and stored at −20 °C.
Immunohistochemistry
Frozen sections were thawed at room temperature. Where
indicated, heat-induced epitope retrieval was performed by
incubating sections in citrate buffered antigen retrieval so-
lution (Dako, Ely, UK) at 90° for 10 min. Sections were
blocked in 5 % normal goat serum (ab7481, Abcam,
Cambridge, UK) for 2 h. Primary antibodies were applied
and incubated overnight at 4 °C. The following primary
antibodies and concentrations were used; rabbit anti-
amyloid precursor protein (PAD CT695, Life Technologies,
Manchester, UK), rat anti-serotonin at 1:1000 (ab6336,
Abcam, Cambridge, UK), rabbit anti-synaptophysin at
1:1000 (ab32127, Abcam, Cambridge, UK), rabbit anti-
GAP43 at 1:1000 (ab11136, Abcam, Cambridge, UK),
mouse anti-glial fibrillary acidic protein (GFAP) at 1:500
(ab7260, Abcam, Cambridge, UK), goat anti-Iba1 at 1:500
(ab5076, Abcam, Cambridge, UK), rabbit anti-Olig2 at
1:500 (P21954, LifeTechnologies, Manchester, UK) mouse
anti-APC (aka anti-CC1) at 1:300 (OP80, Merck Millipore,
Nottingham, UK), Rabbit, and anti-Caspase 3 at 1:500
(ab13847, Abcam, UK).
Goat secondary antibodies diluted to 1:500 of emission
wavelength 488, 555 and 647 nm (Alexa Fluor Life Tech-
nologies, Manchester, UK) were used, except for the goat
anti-Iba1 primary for which a donkey 555 secondary anti-
body was used (Alexa Fluor Life Technologies, Manchester,
UK). Sections were counterstained with 4',6-diamidino-2-
phenylindole (DAPI), then mounted and coverslipped.
Negative controls were performed by excluding the pri-
mary antibody. Cervical cord cranial to the lesion was used
for positive controls for stains assessing axonal sprouting.
Caudal cerebellar peduncle lesions from our laboratory
were used as positive controls for stains assessing myelin-
ation and the immune response. Fluoromyelin at 1:300
(F34651, Life Technologies, Manchester, UK) for 20 min
was used as a myelin stain. BDA staining was performed by
first blocking endogenous peroxidases in 0.3 % H202 and
10 % methanol in PBS for 20 min. Sections were then incu-
bated in avidin/biotinylated enzyme complex (ABC) (PK-
4000, Vector laboratories, Burlingame, CA, USA) for
30 min. The biotinylated signal was then amplified by incu-
bating sections in biotinyl tyramide for 10 min (SAT700,
Perkin Elmer, Waltham, MA, USA). Sections were then in-
cubated in 1:500 avidin overnight at 4 °C. An unamplified
control with ABC and an amplified control without ABC
were also performed.
Image processing
Tissues were visualized at room temperature with a
LSM 700 confocal laser scanning microscope (Zeiss,
Cambridge, UK) and digitalized using Zen 2009 software
(Zeiss, Cambridge, UK) then saved in laser scanning
microscope format (.lsm). Image analysis was performed
using Image J software (US National Institutes of Health,
Bethseda, Maryland, USA).
Immunohistochemical analysis
Tissue samples were analyzed blinded from each group
(ie control, compression or decompressed) at three dif-
ferent regions: 2 mm cranial, 2 mm caudal, and at the
site of compression (lesion).
Cell bodies of neurons and APP plaques and synapto-
physin were analyzed in the grey matter. Oligodendro-
cyte lineage cells, astrocytes and microglia were counted
in both grey and white matter with results presented in
the white matter.
Quantification of immunofluorescent cells
APP+ cells (and plaques), Caspase3+, Iba-1+, Olig2+
(and Olig2+/CC1+), and GFAP+ cells were all counted
manually on 5 random visual fields per region (cranial,
lesion, caudal). Using an Olympus IX71 light microscope
with an Olympus U-PFL-T fluorescent lamp and a TH4-
200 bright-field lamp at 20x magnification, cells that
stained for markers of interest were manually counted
using a hand held tally counter. The obtained cell counts
were averaged to give a representative count for each
specific region.
Quantification of axonal markers
APP and GAP43 immunodensities were quantified in
the white matter using ImageJ software (US National In-
stitutes of Health, Bethseda, Maryland, USA). Images
were converted to grey scale and thresholded. APP and
GAP43 was quantified as the fraction of the area above
the threshold within the region of interest. Results were
recorded as ‘% of positive tissue’.
Synaptophysin in the grey matter was quantified as
density of staining relative to white matter. Fluoromyelin
was quantified in the same manner as synaptophysin, ex-
cept that white matter immunodensities were normal-
ized to grey matter immunodensities. For synaptophysin
and fluoromyelin the process was repeated 16 times per
image and averaged. The value was recorded as ‘Arbi-
trary units’.
Quantification of axonal sprouting
Sprouting of 5HT-labelled raphespinal axons was based
on a modified version of a published technique (Zhao et
al. 2013). Images were examined at 10x magnification
and divided into 2 mm rostral to the lesion, the lesion
Dhillon et al. Acta Neuropathologica Communications  (2016) 4:89 Page 4 of 13
itself, and 2 mm caudal to the lesion. Each section was
then analysed in 0.5 mm increments. The number of
branches coming off an axon were counted, and this was
divided by the total number of labelled axons in that
region to give a count of sprouts per axon. In addition,
5HT immunodensity was quantified as per Lee and
colleagues (Lee et al. 2010) and described above.
Statistical analysis
Results were analyzed using GraphPad Prism Software
Statistics GradPack 18. Immunohistochemistry quantifi-
cations were assessed using a parametric one-way
analysis of variance (ANOVA). When the null hypothesis
was rejected using one-way ANOVA, we then applied a
Fisher’s LSD post test. Functional quantifications were
assessed using two-way ANOVA followed by a Dunnett’s
multiple comparison post-hoc test by defining a control
mean to determine which of the groups had a significant
difference. We pre-determined a significance level
(alpha) of 0.05.
Results
Chronic compression impaired motor function that was
partly reversed by decompression
A pre-clinical model of CSM was established by surgi-
cally inserting an expandable polymer in the dorsal
cervical epidural space of C3/4. The size of the polymer
was chosen to cause moderate neurological signs (see
Methods section: optimisation of compression model).
Following implantation, the polymer expanded resulting
in gradual compression of the spinal cord. Controls
received sham surgeries during which polymers were
transiently inserted into the sub-laminar space, but re-
moved before surgical closure. After a course of 10 weeks
of compression, a laminectomy was conducted and the
implants were removed to decompress the spinal cord
(decompression group). Sham surgery was conducted on
compression only animals and controls.
Animals underwent neurobehavioural testing over a
period of 15 weeks. Subsequently animals were sacrificed
and the tissues analysed. As the main purpose of the
study was to investigate basis of functional recovery, it
was important to first establish functional changes
occurring in the model and following decompression.
Neurobehavioural assessments included the Basso
Beattie and Bresnahan (BBB) locomotor behavior score
[4], and assessment of forepaw and hindpaw slips when
rats were placed on a 16 gauge wire grid (Fig. 1).
One week after compressive surgery, neurological de-
terioration was detected in compressed animals as com-
pared to controls. This was reflected in a significant
drop in BBB scores (mean difference at week + 1 = −5.25;
post-hoc Dunnett’s multiple comparison test following
two-way ANOVA: p < 0.0001). Surgical decompression
after 10 weeks led to gradual functional improvement,
which reached statistical significance after three
weeks (mean difference week + 13 = −2.88, two-way
ANOVA: p < 0.0001, post-hoc Fisher’s LSD test: p <
0.0001–0.001). However, the functional and electro-
physiological recovery (Additional file 1: Figure S1)
remained incomplete.
Compression also induced an increase in the num-
ber of forepaw and hindpaw slips in rats placed on a
wire grid (mean difference at week + 5 = 2.5). Con-
versely, a decrease in forepaw slips (mean difference
at week + 15 = −2.5) was noted after decompressive
surgery (post-hoc Tukey’s multiple comparison test:
p < 0.01). A similar result was seen for hindpaw slips,
which decreased in decompressed rats by 1.38 com-
pared to compressed rats (post-hoc Tukey’s multiple
comparison test: p < 0.0001).
Apoptosis induced by chronic cord compression is
attenuated by decompression
Cellular changes associated with compression and
decompression were studied by immunohistochemistry
on sections cranial, caudal, and at the lesion site. Quan-
tification of caspase3-positive cells demonstrated a sharp
increase in apoptosis associated with chronic cord
compression. The increase of caspase3-positive cells oc-
curred predominantly at the lesion site. Apoptotic cells
were found throughout the white and grey matter of the
spinal cord. After surgical decompression, the density of
caspase3-positive cells significantly reduced (Fig. 2; mean
values at site of compression: control = 30.25, compres-
sion = 87.25, decompression = 44.00).
Chronic compression leads to accumulation of amyloid
precursor protein in neurons
Our hypothesis was that CSM involves axonal injury and
may therefore be amenable to axonal plasticity. Amyloid
precursor protein is a membrane spanning glycoprotein
that is normally found in neurons and was first shown
in the traumatic brain literature to be a marker for dam-
aged axons [43]. Positive staining for APP in axons is
thought to represent accumulation of the protein due to
disruption of axoplasmic flow [44]. In the present study
APP immunostaining was used as a marker of axonal
and neuronal injury. We first quantified intensity of APP
immunoreactivity in white matter tracts, which showed
a marked increase at the site of compression, indicative
of widespread axonal injury (Fig. 2; mean values at lesion
site: control = 2.93, compression = 9.30, decompression
= 1.23). Moreover, we assessed the number of APP-
positive neurons with intact morphology in the grey
matter, which are thought represent a potentially revers-
ible stage of injury. Significantly increased APP expres-
sion in neuronal cell bodies was found in compressed
Dhillon et al. Acta Neuropathologica Communications  (2016) 4:89 Page 5 of 13
-1 +1 +3 +5 +7 +9 +1
1
+1
3
+1
5
14
16
18
20
Weeks post compression
B
B
B
 s
co
re
BBB score
Control
Compression only
Decompression
Compression
****
***
**** **** **** **** ****
Decompression
CSM model
-1 +1 +3 +5 +7 +9 +1
1
+1
3
+1
5
0
2
4
6
Weeks post compression
F
o
re
p
aw
 s
lip
s
Forepaw slips
Decompression
**
Compression
-1 +1 +3 +5 +7 +9 +1
1
+1
3
+1
5
0
2
4
6
Weeks post compression
H
in
d
p
aw
 s
lip
s
Hindpaw slips
Decompression
**** ****
****
Compression
Charles Howe 
b
c
d
a
Fig. 1 a Chronic cord compression was induced by surgical implantation of an expandable polymer underneath the posterior arches of C3/4.
Sham surgery was conducted on controls (each experimental group n = 5). b Locomotor behaviour was assessed using open-field Basso Beattie
Bresnahan (BBB). Spinal cord compression resulted in significant neurological deterioration within 1 week (****p< 0.0001). After 10 weeks, a laminectomy
was performed and the implants removed. In the decompressed group, scores improved significantly three weeks after surgery (****p< 0.0001). Induction
of SC compression also increased the number (c) forepaw and (d) hindpaw slips of rats placed on a grid as compared to controls. On the other hand,
a significant reduction of forepaw and hindpaw slips was detected following surgical decompression (**p< 0.01, ****p< 0.0001)
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rats above, below, and at the lesion centre (mean values
at lesion site: control = 4.00, compression = 15.70,
decompression = 7.75). This further supports the notion
that chronic cord compression induces neuronal stress
(Fig. 2). Finally, we also quantified the number of APP-
positive plaques [13]. Cord compression induced a
significant increase of APP plaques in the grey matter
(mean values at lesion site: control = 3.00, compression
= 6.40, decompression = 5.00; data not shown).
Surgical decompression reverses APP accumulation
Following surgical decompression, a pronounced de-
crease of APP immunoreactivity in white matter tracts
and APP-positive neurons in grey matter was detected
above, below, and at the lesion site (Fig. 2). The levels of
APP expression in white matter tracts and the number
of APP-positive neurons after surgery approached levels
of non-injured controls. In contrast, the number of
APP-positive plaques did not change.
Fig. 2 To assess the consequences of compression and decompression on cell apoptosis, sections were stained for Caspase-3. a-e Quantification of
Caspase3-positive cells cranial, caudal and at the lesions sites demonstrated increased levels of apoptosis as a result of chronic cord compression at the
lesion site (****p< 0.0001). Conversely, the number of apoptotic cells decreased significantly approaching normal levels following surgical decompression
(****p< 0.0001). To assess neuronal pathology, sections were stained for APP. Quantification of APP+ axons in white matter tracts demonstrated a
significantly increased APP expression as a consequence of compression (*p< 0.05, ****p< 0.0001), which subsided after decompression (***p< 0.001,
****p< 0.0001). Similarly, the number of APP+ but morphologically intact neurons in the grey matter increased as a result of compression cranial, caudal
and at the lesions site (****p< 0.0001), and decreased following decompression to levels observed in controls (**p< 0.01, ***p< 0.001, ****p< 0.0001).
In addition, the number of APP+ plaques in the grey matter significantly increased after decompression (*p< 0.05, **p< 0.001), but failed to decrease
following decompression, indicating a sub-population of cells that was irreversibly damaged. Scale bar: c-h= 100 μm
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Chronic compression results in degeneration of
serotonergic axons and loss of synapses
To further assess neuronal damage, serotonergic axons of
the descending raphespinal tract were investigated in the
spinal cord. At the centre of compression, a significant loss
5HT-positive axons occurred (Fig. 3; mean values at lesion
site: control = 0.36, compression = 0.08, decompression =
0.30). To further assess the functional connections, immu-
nohistochemical staining for synaptophysin was conducted.
Compression groups had lower levels of synaptophysin
immunostaining compared to control, suggesting that
chronic cord compression results in a loss of synapses at
the site of compression (data not shown). Furthermore,
compression reduced the number of HT5+/synaptophy-
sin + axons, demonstrating loss of descending serotonergic
input (Fig. 3; mean values at lesion site: control = 45.4,
compression = 15.60, decompression = 47.75).
Surgical decompression induces axonal sprouting and
formation of new synapses
Previous studies of acute SCI indicate that serotoner-
gic axons may have an increased propensity to sprout
in response to injury [23] and accordingly, could
serve as a potentially sensitive assay of axonal plasti-
city. We found that serotonergic fibre number at the
lesion site increased significantly following surgical
decompression. Regenerative sprouting of serotonergic
fibres was most pronounced caudal to the lesion,
where the decompressed group displayed significantly
more serotonergic axons compared to all other
groups (Fig. 3a; mean values below previous compres-
sion: control = 0.380, compression = 0.220, decompres-
sion = 0.638).
However, were the sprouting raphespinal fibres able to
form functional connections and so contribute to the
Fig. 3 To further explore the effects of spinal cord compression and decompression serotonergic axons were visualised by immunohistochemical
staining for 5HT. a-d Compression resulted in a significant decrease of 5HT positive axons in white matter tracts above and at the site of cord
compression (**p < 0.01, ****p < 0.0001. On the other hand, the presence of 5HT fibres increased significantly at and below of the area of cord
compression following surgical decompression. e-h Quantification of 5HT+/synaptophysin + axons in the grey matter demonstrated a decrease in
functional serotonergic innervation at and below the lesion site (**p < 0.01, ****p < 0.0001). Following decompression, a significant increase of
5HT+/synaptophysin + axons was detected (***p < 0.001, ****p < 0.0001), which points to the presence of axonal sprouting. j-l Axonal sprouting
was further confirmed by immunohistochemistry for GAP43, which indicated an increase of GAP44+ axons below the lesion site following
decompression (***p < 0.001, ****p < 0.0001). Scale bar: b-d, f-h = 100 μm; j-l = 30 μm
Dhillon et al. Acta Neuropathologica Communications  (2016) 4:89 Page 8 of 13
functional improvement seen following decompression?
This is difficult to demonstrate definitively, but one line
of evidence that has been used as a correlate of
functional synapses is the co-localisation of synaptophy-
sin with HT5 [6]. Quantification of synaptophysin-
positive serotonergic fibres demonstrated a significant
reduction in HT5+/synaptophysin + axons in chronically
compressed spinal cords at and caudal to the lesion
(Fig. 3e; mean values at lesion site: control = 0.285,
compression = 0.112, decompression = 0.233). After de-
compression the proportion of HT5+/synaptophysin +
axons increased significantly, reaching levels seen in
controls at the lesion site, and increasing above control
levels caudal to the lesion. Sprouting serotonergic axons
were therefore likely to be forming synapses.
Another way to assay plasticity is to test for surrogate
markers such as GAP-43. This membrane bound protein is
expressed in extending axons and its expression likely rep-
resents a high-growth state [47]. Following decompression,
GAP-43 expression was strongly induced above, below, and
at the lesion itself (Fig. 3j; mean values at lesion site:
control = 5.0, compression = 6.0, decompression = 13.2).
Effects of compression and decompression on microglia,
astrocytes and myelin
To characterize the innate immune response, Iba-1-
positive microglia were quantified. Following compression,
a significant increase in the number of Iba-1-positive cells
occurred, above, below and at the site of maximal
compression. Once the pressure was relieved, the inflam-
matory response subsided and the number of microglia
reduced approaching background levels in all areas inves-
tigated (Fig. 4a-d; mean values at lesion site: control =
121.6, compression = 239.4, decompression = 164.0).
We next quantified the reaction of astrocytes to com-
pression and decompression by staining for GFAP
(Fig. 4e-h). We found a marked loss of GFAP-positive as-
trocytes at the site of compression. This was in contrast to
Fig. 4 a-d The microglial response was assessed by staining for Iba1. Compression induced a significant accumulation of Iba1+ cells above,
below, and at the site of cord compression (**p < 0.01, ***p < 0.001, ****p < 0.0001). Following decompression, Iba + microglia reduced above and
at the site of compression (**p < 0.01). e-h) Interestingly, compression resulted in a marked loss of GFAP-positive astrocytes at the level of the le-
sion (**p < 0.01). Conversely, a marked astrocytosis was detected above and below the site of compression (**p < 0.01, ***p < 0.001). The absence
of astrocytes at the area of compression and the reactive astrocytosis above and below persisted following decompression. i-l Visualization of
myelin with fluorescent dies (Fluoromyelin) failed to demonstrate frank demyelination. Scale bar: b-d = 0 μm; f-h, j-l = 100 μm
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the findings above and below of the lesion, where a
significant increase in GFAP immunoreactivity occurred.
Decompression had no detectable effects on GFAP
staining: GFAP levels at the site of compression remained
low whereas increased levels of astrocytes persisted above
and below the lesion (mean values at lesion site: control =
63.4, compression = 30.2, decompression = 46.5).
Finally, we stained membranous components in the
spinal cords using a fluorescent dye (fluoromyelin). We
observed a decrease in fluorescence in the compressed
group compared to controls caudal to the lesion. More-
over, fluorescence intensity in the decompressed group
above the lesion was decreased compared to compressed
animals (Fig. 4i-l, mean values at lesion site: control =
1.146, compression = 1.208, decompression = 1.116).
Discussion
Recapitulation of clinical CSM
We propose a preclinical model of CSM that resembles
a moderate clinical phenotype in human CSM patients.
Histological analysis demonstrated that chronic cord
compression compromised axons and damaged neurons,
and resulted in loss of axonal and synaptic integrity.
These findings faithfully reproduce findings of human
autopsy studies of CSM patients, which detected axonal
loss [25] and an increase in APP immunoreactivity at
the compression epicentre [51]. They are also consistent
with results of other expandable polymer rat models of
CSM that found a correlation between compression and
functional impairment [28, 30]. In the present model,
hind-forelimb coordination assessed by the BBB score
and quantification of hindpaw slips proved to be more
consistent for monitoring neurological deficits than the
quantification of forepaw slips. A potential explanation
is the discrepancy in the extent of innervation to the
forepaws as compared to the hindpaws.
The hypothesis of the present study was that decom-
pression would trigger and enable a regenerative re-
sponse in axons. Our results demonstrated that surgical
decompression is able to partially restore function. This
fits well with observations in human patients, where
improvements following surgery have been reported
independent of disease severity [16, 17].
Surgical decompression increases spinal cord blood
flow and results in changes in the metabolic milieu.
These changes by themselves may result in immediate
improvements of cellular and axonal functions. However,
in the present model functional recovery did not imme-
diately follow decompression but occurred gradually
over a three-week period. This resembles the expected
time frame of axonal plasticity. Similarly, the benefits
from surgical decompression in humans do not manifest
themselves immediately. Systematic studies of CSM
patients that were decompressed indicate that improvements
occur over several months and can be between 3 and
12 months post-operatively [17]. Follow up investiga-
tions after 24 months indicate that these improve-
ments often persist, and that surgery therefore can
lead to continued benefits for CSM patients [16]. This
also suggests that surgical decompression is able to
halt the tissue destruction caused by chronic cord
compression.
Similar to human CSM, the present model is based on
chronic compression of the spinal cord. However, expan-
sion of the implant after implantation is unlikely to fully
reflect the slowly progressive nature of human disease.
Moreover, compression in the present model is only
mediated from posterior, whereas in human CSM it can
occur selectively anterior, posterior, or circumferentially.
The method of decompression in the present model is
consistent with a posterior decompression in human
patients, which has been shown to be comparable to
anterior decompression in terms of post-operative out-
come [15, 32].
Chronic cord compression causes axonal degeneration and
neuronal loss
Quantification of Caspase3-positive cells demonstrated
increased apoptosis at the level of compression. In
addition, our findings indicated substantial axonal and
neuronal injury: APP intensity in white matter tracts
was markedly increased at the site of compression. The
accumulation of APP in axons suggests that there was a
degree of cytoskeletal breakdown in CSM. Amyloid
precursor protein is transported by fast axonal traffick-
ing and accumulates at detectable levels at defects in the
cytoskeleton [43]. Whether this is due to direct mechan-
ical trauma, ischaemia, or some other mechanism
remains to be established. One possible explanation for
the observed APP accumulation is that anterograde
transport may be affected more than retrograde
transport.
Cord compression also induced accumulation of APP in
neurons in the central grey matter above, below and at the
site of compression. APP accumulation in morphologically
intact neurons appeared to be reversed following decom-
pression, indicative of sublethal damage. However, the
number of APP-positive plaques was not reversible.
Although its role is only partially understood, descend-
ing serotonergic input to the spinal card by the raphesp-
inal tract has implicated in the control of the central
pattern generator (for an excellent review see [19]). Quan-
tification of descending serotonergic fibres as a relevant
subset of axons in the spinal cord detected a profound loss
of serotonergic axons at the epicentre as a result of spinal
cord compression. The implied loss of connectivity was
directly reflected by the loss of synapses, as indicated by
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the loss of synaptophysin staining above and at the level of
compression.
Taken together, our findings demonstrate that chronic
cord compression causes a significant neuronal pheno-
type with profound axonal injury. This fits well with
observations in human post mortem studies of CSM
patients demonstrating a prominent loss of axonal and
neuronal elements.
To our knowledge, the present study is the first to
systematically study the cellular and molecular conse-
quences of surgical decompression in a model of CSM. As
discussed above, decompression resulted in a gradual
improvement of function, within a time frame that is
suggestive of an underlying regenerative/plastic response.
Assessment of Caspase3 immunohistochemistry demon-
strated a significant reduction in apoptosis with levels
reaching base line after 5 weeks following decompression.
Surgical decompression therefore terminated the ongoing
cell loss via apoptosis. Similarly, the reduction in APP im-
munoreactivity suggests that surgical decompression is
able to halt the cellular damage caused by chronic cord
compression. This is consistent with clinical data demon-
strating persistent improvements following surgical
decompression [16]. However, long term follow up studies
are required to rule out that prolonged compression of
the spinal cord does not trigger a slowly progressive
neurological decline, as is often seen in other neurodegen-
erative conditions [48].
Surgical decompression enables axonal plasticity and
promotes the formation of synapses
Assessment of 5HT immunohistochemistry following
decompression demonstrated a marked increase of sero-
tonergic fibres, above, below and at the site of previous
compression. This increase is likely mediated by a local-
ized sprouting response of serotonergic fibres. The no-
tion that the observed increase of serotonergic fibres is a
result of axonal regeneration is supported by the con-
comitant presence of Gap43, a protein that is expressed
during high-growth states of axons [5, 7], and which was
detected above, below, and at the site of previous com-
pression. In addition, we found that following decompres-
sion, synaptophysin was re-expressed. Synaptophysin
expression is thought to represent functional synapses [12,
20, 41]. Taken together, these data demonstrate that surgi-
cal decompression triggers a regenerative response in
axons that leads to the establishment of new, functional
connections.
Glial reactions to surgical decompression
We observed a marked microglial response to compres-
sion which extended to the adjacent tissue above and
below the epicentre. Following decompression, microglia
activation was reduced. The fact that microglia are
activated in CSM was expected and corresponds well
with findings of other CSM models [22, 24, 28, 51] and
post mortem studies of CSM [51]. Similarly, PET studies
conducted in clinical patients confirmed that cord com-
pression in CSM is associated with inflammation [18].
In the present study, we did not find evidence of gross
myelin destruction in our model. Compression resulted
in decreased fluoromyelin below the lesion site, whereas
decompression led to a decrease above the compression
site. These findings are difficult to interpret and warrant
further investigation with more sensitive techniques. An-
other striking finding was the loss of GFAP staining at
the epicenter of compression with a concomitant in-
crease of GFAP+ cells above and below the are of com-
pression. Interestingly, astrocytes were unable to recover
after decompression and thus the loss of GFAP immu-
nohistochemistry persisted in the present study. Astro-
cytes are known to play an important role in the
formation of the glial scar, the maintenance of the BBB,
and regenerative responses, including remyelination
[46]. Experimental depletion of astrocytes in various in-
jury paradigms is associated with increased spread and
persistence of inflammatory cells, more persistent loss of
BBB function, and increased tissue damage [11, 14, 36,
49]. It is possible that the reduced astrocyte activity may
have facilitated axonal sprouting and attenuated demye-
lination, as seen following experimental modulation of
astrocytes in experimental models of SCI [34]. Unfortu-
nately, there are very few manuscripts investigating
astrocytosis in human CSM and quantitative data re-
mains wanting [45].
There are a number of limitations to the present study.
Although our study demonstrated functional improve-
ment based on behavioural tests (electrophysiological
findings, Additional file 1: Figure S1) and concomitant
histological evidence of axonal plasticity, a causal rela-
tionship between the two has not been formally demon-
strated. Nevertheless, it is likely that the observed
functional changes can be attributed to neuronal and
axonal changes: 1) the loss of function observed in our
model correlated well with the damage of neuronal ele-
ments. 2) The functional recovery observed after decom-
pression, was notably associated with regenerative
growth of axons. 3) Importantly, re-expression of synap-
tophysin is considered a surrogate marker of functional
synapses as it is only expressed when active synapses are
formed. 4) The time lag with which the improvements
were observed, fits well with the time frame that is
expected for successful axonal plasticity. However, the
present study did not assess plasticity at other levels
such as the cortex, subcortical nuclei and lumbar central
pattern generators, which may also contribute to the
improvements observed after surgical decompression
[10]. Further studies are needed to assess alternative
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mechanisms of neural plasticity and conduct a more de-
tailed and sensitive analysis of motor and sensory func-
tions, specifically also including forepaw functions,
which are clinically of significant relevance.
Conclusions
CSM is a common and debilitating disease that affects a
large number of individuals. The economic burden of
the disease has not been calculated yet but is likely to be
large. With continued aging of the populations in the in-
dustrial world, the incidence and prevalence of CSM is
expected to increase. Concentrated efforts are therefore
required to develop therapeutic options for promoting
functional recovery from CSM.
The present model allows several clinically relevant and
important questions to be addressed. For example, age has
recently been recognized as an important determinant of
functional outcome following surgery for CSM [37]. But
the question how age affects the recovery from chronic
compression remains unclear. Further questions include,
how the duration of compression influences symptom se-
verity and the ability to recover from CSM? Does chan-
ging the severity of cord compression alter the cellular
and molecular response, how does it affect recovery? Im-
portantly, our model will also permit to gain further in-
sights in the pathophysiology of the disease and
investigate treatment options for ameliorating the neuro-
logical deficits in CSM. Our results indicate that promot-
ing axonal plasticity is one potential strategy to improve
neurological function in individuals affected by CSM.
Additional file
Additional file 1: Figure S1. Functional changes in the present model
were reflected in sensory evoked potentials. For technical reasons only
two rats were recorded in each group. Speed and amplitude of impulses
transmitted from the tibial nerve in the lower limb to recording sites in
the gracile nucleus of the lower brainstem (spinal) and the sensory cortex
(cortical) were measured. Compression resulted in a decreased
amplitudes of cortical and spinal waveforms. After decompressive surgery
these increased but did not reach baseline amplitudes. (PDF 117 kb)
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